Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency.

R C Hubbard, … , D B Czerski, R G Crystal

*J Clin Invest.* 1989;84(4):1349-1354. [https://doi.org/10.1172/JCI114305](https://doi.org/10.1172/JCI114305).

Alpha 1-Antitrypsin (alpha 1AT) deficiency is characterized by insufficient amounts of alpha 1AT to protect the lower respiratory tract from neutrophil elastase, resulting in emphysema. Yeast-produced recombinant alpha 1AT (rAAT) has normal antielastase function but is associated with high renal clearance, thus obviating chronic intravenous administration. As an alternative, we evaluated aerosol administration of rAAT to alpha 1AT-deficient individuals. After aerosol administration of single doses of 10-200 mg of rAAT, epithelial lining fluid (ELF) alpha 1AT antineutrophil elastase defenses were augmented in proportion to the dose of rAAT administered. ELF alpha 1AT levels and antineutrophil elastase capacity 4 h after 200 mg rAAT aerosol were increased 40-fold over preaerosol levels, and were fivefold increased over baseline at 24 h after aerosol administration. rAAT was detectable in serum after aerosol, indicating that the lower respiratory tract epithelium may be permeable to rAAT, and that aerosolized rAAT is capable of gaining access to lung interstitium. No adverse clinical effects were noted. These observations demonstrate that aerosol administration of rAAT is safe and results in significant augmentation of lung antineutrophil elastase defenses, suggesting this method is a feasible approach to therapy. Because this approach is clinically unproven, further studies will be necessary to establish the long-term clinical efficacy of aerosol therapy in alpha 1AT deficiency.

Find the latest version:

http://jci.me/114305-pdf
Recombinant DNA–produced $\alpha_1$-Antitrypsin Administered by Aerosol Augments Lower Respiratory Tract Antineutrophil Elastase Defenses in Individuals with $\alpha_1$-Antitrypsin Deficiency

Richard C. Hubbard, Noel G. McElvaney, Stephanie E. Sellers, Jane T. Healy, Dorothy B. Czerski, and Ronald G. Crystal

Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892

Abstract

$\alpha_1$-Antitrypsin ($\alpha$AT) deficiency is characterized by insufficient amounts of $\alpha$AT to protect the lower respiratory tract from neutrophil elastase, resulting in emphysema. Yeast-produced recombinant $\alpha$AT (r$\alpha$AT) has normal antielastase function but is associated with high renal clearance, thus obviating chronic intravenous administration. As an alternative, we evaluated aerosol administration of r$\alpha$AT to $\alpha$AT-deficient individuals. After aerosol administration of single doses of 10–200 mg of r$\alpha$AT, epithelial lining fluid (ELF) $\alpha$AT antineutrophil elastase defenses were augmented in proportion to the dose of r$\alpha$AT administered. ELF $\alpha$AT levels and antineutrophil elastase capacity 4 h after 200 mg r$\alpha$AT aerosol were increased 40-fold over preaerosol levels, and were fivefold increased over baseline at 24 h after aerosol administration. r$\alpha$AT was detectable in serum after aerosol, indicating that the lower respiratory tract epithelium may be permeable to r$\alpha$AT, and that aerosolized r$\alpha$AT is capable of gaining access to lung interstitium. No adverse clinical effects were noted. These observations demonstrate that aerosol administration of r$\alpha$AT is safe and results in significant enhancement of lung antineutrophil elastase defenses, suggesting this method is a feasible approach to therapy. Because this approach is clinically unproven, further studies will be necessary to establish the long-term clinical efficacy of aerosol therapy in $\alpha$AT deficiency.

Introduction

Alpha 1-antitrypsin ($\alpha$1AT) deficiency is a genetic disorder characterized by low plasma and lung levels of $\alpha$1AT and the development of emphysema by the third to fourth decades (1, 2). The deficiency of $\alpha$AT in the lower respiratory tract is central to the pathogenesis of the emphysema due to the critical role of $\alpha$AT in protecting the alveolar structures against neutrophil elastase, a broad-spectrum protease capable of degrading all major protein components of the alveolar interstitium (1–3). As a result of the low lung levels of $\alpha$AT, neutrophil elastase released from neutrophils in the lower respiratory tract is free to attack alveolar walls, resulting in the gradual destruction of lung parenchyma and the eventual development of emphysema (1–4). These biologic abnormalities in the lower respiratory tract can be reversed with $\alpha$AT augmentation therapy, in which human plasma–purified $\alpha$AT is administered intravenously on a weekly (2, 5) or monthly (6) basis, thus reestablishing the antineutrophil elastase protective screen of the lower respiratory tract (2, 5, 6).

An alternative approach to therapy of $\alpha$AT deficiency is to use recombinant DNA–produced $\alpha$AT (r$\alpha$AT) to augment the antineutrophil elastase screen of the alveolar structures. This approach has been made feasible by the demonstration that r$\alpha$AT produced in yeast under the direction of a normal human $\alpha$AT cDNA function as an inhibitor of neutrophil elastase in a fashion identical to that of the normal human $\alpha$AT (7, 8). However, unlike human plasma $\alpha$AT, r$\alpha$AT lacks carbohydrate side chains (7, 8). As a result, when r$\alpha$AT is administered intravenously it has a much shorter plasma half-life than does normal $\alpha$AT (7). In part, this occurs because a large amount of the administered r$\alpha$AT is cleared by the kidney, whereas no natural $\alpha$AT appears in the urine after intravenous administration (6, 7). Compared with human plasma $\alpha$AT, intravenous administration of r$\alpha$AT thus would require far more $\alpha$AT to raise serum levels sufficient to protect the lung, and the large bulk of protein passing through the kidney may lead to renal disease, thus obviating this route of administration.

It may be possible, however, for r$\alpha$AT to be used therapeutically to augment lung antielastase defenses if it were targeted directly to the lower respiratory tract, i.e., given by aerosol. In this regard, studies in experimental animals have demonstrated that aerosol administration permits the delivery of intact, functional r$\alpha$AT to the lower respiratory tract, and that the r$\alpha$AT diffuses into the alveolar interstitium, the site that must be protected in $\alpha$AT deficiency (8). With this background, this study was designed to evaluate the feasibility of administering r$\alpha$AT via aerosol to humans with $\alpha$AT deficiency.

For aerosolization of r$\alpha$AT to be considered as a form of therapy for $\alpha$AT deficiency several criteria must be met, including (a) the r$\alpha$AT must be delivered to the lower respiratory tract of $\alpha$AT-deficient individuals as an intact, functional protein; (b) it must be possible to deliver an aerosol dose of r$\alpha$AT that results in significant augmentation of the antineutrophil elastase defenses of the lower respiratory tract in
α1AT-deficient individuals; (c) rAAT must remain active as an inhibitor of elastase long enough for intermittent aerosol administration to be practical; (d) rAAT must be able to pass through the alveolar tissues, thus affording protection to the interstitial compartment; and (e) it must be safe. In this study, we demonstrate that these criteria can be met, and thus it is therefore reasonable to consider aerosol administration of rAAT as a form of therapy for α1AT deficiency.

Methods

Recombinant α1AT preparation. The rAAT used in this study, supplied by Cooper Biochemicals (Mountain View, CA) and Ciba-Geigy Corp. (Summit, NJ), was produced by yeast transformed with an expression plasmid containing a human α1AT cDNA encoding the mature normal M1 (Val137) human α1AT protein (7, 8). This rAAT preparation has a molecular mass of 45 kD, is identical to human plasma α1AT except for an additional NH2-terminal methionine and the lack of the three carbohydrate side chains in plasma α1AT, and functions in an identical manner as human plasma α1AT as an inhibitor of neutrophil elastase (7, 8).

Aerosol-generating system. rAAT was aerosolized using a compressed air driven nebulizer (Mallinckrodt) selected on the basis of its ability to generate an aerosol with droplets of optimal size (<3 μm aerodynamic diameter) for deposition in the lower respiratory tract (8, 9). rAAT aerosolized in this fashion retains its structure and function as an inhibitor of neutrophil elastase (8).

Evaluation of the ability of the aerosol device to deliver aerosol to the alveolar regions was estimated to be in the range of 10–20%, estimated by quantitating the proportion of a starting dose of technetium-99m-labeled diethylenetriamine pentaacetic acid impacting in the lower respiratory tract after nebulization to α1AT-deficient individuals.

Study population. Six Z homozygotes were entered into a preliminary study to evaluate the potential antigenicity of the rAAT (see below). These individuals (five males, one female, average age 41 ± 11 yr) were typical of α1AT deficiency with emphysema and α1AT serum levels of 4.3 ± 0.4 μM (all α1AT levels are presented in micromolar units using a true laboratory standard) (2). All data are presented as mean±SEM and all statistical comparisons were made using the two-tailed t test.

The study population used for administration of the aerosol of rAAT consisted of 16 α1AT-deficient individuals (10 men, 6 women; 39±2 yr). There were 14 Z homozygotes (α1AT serum levels 4.5±0.5 μM) and 2 Nullgranie homozygotes (α1AT levels 0), verified by measurement of serum α1AT levels, isoelectric focusing of serum, family studies, and genotyping using specific oligonucleotide probes (10, 11). 5 individuals were lifelong nonsmokers, 10 were exsmokers (11±±2 pack-yr), and 1 was present smoker (13 pack-yr). All had evidence of mild-to-moderate emphysema, based on physical examination, chest x ray, xenon-133 ventilation scans, technetium-99m-labeled macroaggregated albumin scans and lung function (vital capacity 100±15% predicted, total lung capacity 111±12% predicted, forced expiratory volume in 1 s [FEV1] 78±28% predicted, and diffusing capacity for carbon monoxide 86±25% predicted [corrected for hemoglobin and volume]) (12). Resting arterial blood gases showed PaO2 87±12 Torr, PCO2 37±3 Torr, and pH 7.40±0.03. Individuals with severe emphysema were excluded from the study because of the inability to use bronchoalveolar lavage to study the effect of aerosol.

Study design. Before administering rAAT by aerosol, a preliminary investigation was carried out to determine the safety of administration of rAAT to α1AT-deficient individuals. Over a 6-mo period, rAAT was administered subcutaneously to six Z homozygotes. Three individuals received 1 mg and three individuals received 10 mg at biweekly intervals over a 10-wk period. Immunologic assessment included skin prick and intradermal tests to detect immediate or delayed hypersensitivity reactions, blood lymphocyte blastogenesis to yeast protein extract or to rAAT, measurement of specific antieast, anti-rAAT, and antihuman α1AT antibodies in serum, and quantification of serum α1AT levels. There were biweekly assessments of serum chemistries, complete blood counts, erythrocyte sedimentation rate, coagulation profile, urinalysis, creatinine clearance, chest x rays, and lung function studies.

The aerosol study was designed to evaluate the biologic parameters relevant to the rAAT after a single-dose aerosol administration of rAAT. The study was done in two phases. First, escalating single doses of rAAT were administered by aerosol to α1AT-deficient individuals (10 mg, n = 2; 50 mg, n = 2; 100 mg, n = 5; and 200 mg, n = 4). Second, an additional three individuals were evaluated at the 200-mg dose to determine the time dependency of biologic parameters in the lower respiratory tract modified by aerosol. For both phases of the study, before aerosol administration of rAAT, a baseline bronchoalveolar lavage was performed (2) to determine epithelial lining fluid (ELF) levels of α1AT and antineutrophil elastase capacity. The lavage procedure was repeated 4 or 24 h after aerosol to assess the effect of rAAT aerosol administration of ELF α1AT levels and antineutrophil elastase capacity.

To evaluate whether rAAT administered by aerosol diffused across the lower respiratory tract and reached the blood, we capitalized on the knowledge that the two Nullgranie falls homozygotes had no α1AT in the serum (13), and thus any α1AT that was detectable must have come from the aerosolized rAAT. The Nullgranie falls individuals were treated with a single dose of aerosolized rAAT and serum samples were taken at 4, 8, 24 and 48 h after the aerosol and evaluated for α1AT by ELISA (2).

Serum was obtained preaerosol, 2 and 4 wk after aerosol administration for measurement of antibodies against rAAT, yeast, and plasma α1AT. Subcutaneous and intradermal skin testing for hypersensitivity to rAAT or yeast proteins was performed preaerosol and 4 wk after aerosol administration. At multiple times in the 48 h after each aerosol administration, serum chemistries, complete blood counts, and clotting studies were evaluated. The status of the lungs was evaluated by chest x ray, pulmonary function tests, and arterial blood gases, obtained preaerosol, 4 h, 1, d, 1 mo after aerosol administration.

To evaluate epithelial lining fluid for the presence and form of rAAT after aerosol administration, Western blot analysis of 50-fold concentrated bronchoalveolar lavage fluid was carried out by lopolhizing the fluid, reconstituting with H2O, and dialyzing against phosphate buffered saline, pH 7.5. Samples were evaluated by 7.5% SDS-PAGE and Western analysis with a polyclonal anti-α1AT antibody (8).

Measurement of ELF α1AT levels was done in quadruplicate by ELISA (2) and referenced to the volume of ELF as determined by the urea method (14). To verify that the α1AT measured by ELISA represented intact rAAT, Superose-12 molecular sieve chromatographic analysis of concentrated lavage fluid of a Z homozygote was carried out after aerosolization of 200 mg rAAT. The 1-mL fractions of the 100-mL column eluate were individually assayed for α1AT by ELISA.

Determination of the antineutrophil elastase capacity of ELF was performed as previously described (2) using a titrated neutrophil elastase standard. To demonstrate the ability of rAAT present in ELF after aerosol to combine with neutrophil elastase, samples of ELF derived from lopolhized bronchoalveolar lavage fluid from a Nullgranie falls homozygote were incubated (5 min, 25°C) with human neutrophil elastase (30 μM). The samples were then applied to a 7.5% SDS polyacrylamide gel and transferred to nitrocellulose for Western blotting.

Results

Initial safety assessment. The 6-mo skin-testing evaluation of rAAT suggested that the rAAT would not be recognized by the immune system as foreign. Despite biweekly "immunization" with rAAT, no abnormal clinical or immunologic parameters were observed, leading to the conclusion that it was safe to proceed with aerosolization of rAAT.

Hubbard, McElvaney, Sellers, Healy, Czerski, and Crystal
Dose dependency. Administration of varying amounts of rAAT to α1AT-deficient individuals resulted in a dose-response relationship for both the quantity of α1AT present in the lower respiratory tract and the neutrophil elastase inhibitory capacity of ELF. Aerosol administration of single doses of 10, 50, 100, or 200 mg rAAT resulted in progressive augmentation of total ELF α1AT levels (preaerosol compared with the 24-h postaerosol level after administration of 200 mg rAAT, \( P < 0.01 \)) (Fig. 1A). Not only were total ELF α1AT levels increased, but the ability of the ELF to inhibit neutrophil elastase was also increased after rAAT aerosol (preaerosol compared with 24 h after aerosol administration of 200 mg rAAT, \( P < 0.01 \)) (Fig. 1B). Expression of α1AT levels and antineutrophil elastase capacity relative to the concentration of albumin in lavage fluid yielded the same results: preaerosol, 2.6±1.1 μg α1AT/μg albumin; after 10 mg aerosol, 2.5±2.4 ng α1AT/μg albumin; after 100 mg aerosol, 7.2±2.5 ng α1AT/μg albumin; after 200 mg aerosol, 13.2±3.0 ng α1AT/μg albumin. Bronchoalveolar lavage fluid antineutrophil elastase capacity per microgram albumin yielded similar results (data not shown). When evaluated 1 mo later, for all individuals, there was a complete reversion to preaerosol levels of α1AT and antineutrophil elastase capacity (\( P > 0.5 \), all comparisons).

Structure of the rAAT delivered by aerosol. Analysis of lavage fluid demonstrated that the rAAT delivered by aerosol to the lower respiratory tract remained intact during the delivery process. As demonstrated by Western blot analysis of concentrated lavage fluid obtained from a Z homozygous individual 24 h after aerosol administration of 200 mg rAAT, administration of rAAT via the aerosol route resulted in clearly detectable amounts of intact rAAT in lower respiratory tract ELF (Fig. 2). Using SDS acrylamide electrophoresis and a polyclonal antibody that recognizes both human plasma α1AT and rAAT, plasma α1AT with its molecular mass of 52 kD (lane 1), is distinguishable by the difference in mass from rAAT, with a molecular mass of 45 kD (lane 2). Before aerosol administration of rAAT, the ELF contained only the expected endogenous 52 kD α1AT (lane 3). In contrast, after aerosol administration of rAAT, ELF contained both the 52-kD endogenous plasma α1AT and the 45-kD rAAT (lane 4). The rAAT present in the ELF was intact, and looked identical to the rAAT standard that had not been aerosolized, i.e., the protein did not undergo fragmentation or was otherwise reduced in size either during aerosol or once deposited in the lung. Furthermore, consistent with the ELISA data, comparison of the relative intensity of the endogenous α1AT and rAAT on the SDS gels suggested that even 24 h after delivery, 200 mg aerosol administration of rAAT provides more α1AT to the epithelial surface than does the endogenous α1AT of the α1AT deficient individual. Additional evidence that recovered rAAT was not fragmented was provided by chromatography of the concentrated lavage fluid; evaluation of all fractions by α1AT-specific ELISA demonstrated all α1AT (endogenous plus rAAT) in the 42-55-kD range.

Time dependency. Evaluation of ELF levels of α1AT at different times after a single aerosol dose of rAAT demonstrated a time dependent change in the amount of α1AT in ELF (Fig. 3). Analysis of lavage fluid obtained 4 h after 200 mg rAAT aerosol showed that the ELF levels of α1AT were elevated >40-fold over preaerosol ELF α1AT levels (\( P < 0.01 \)). By 24 h, the ELF α1AT levels had fallen, but were still fivefold over preaerosol levels (\( P < 0.01 \)). When viewed in the context of the ELF levels of α1AT in normals, single-dose administration of 200 mg rAAT normalized ELF α1AT levels in α1AT-

---

**Figure 1.** Effect of increasing doses of aerosolized rAAT on ELF α1AT levels and ELF antineutrophil elastase (NE) capacity of Z homozygous individuals. Lavage was performed before or 24 h and 1 mo after aerosol of rAAT. (A) Total α1AT levels in lavage fluid measured by ELISAs. (B) Anti-NE capacity determined by the ability lavage fluid to inhibit a fixed amount of human neutrophil elastase. Concentrations are expressed relative to the volume of ELF recovered.

**Figure 2.** Evaluation of the structure of (rAAT) in lavage fluid of a Z homozygous individual after the aerosol administration of rAAT. Shown is a Western blot of a SDS-PAGE of purified α1AT standards and of concentrated lavage fluid before and 24 hr after administration of 200 mg rAAT. Lane 1, human plasma purified α1AT standard; lane 2, rAAT standard; lane 3, lavage fluid from a Z homozygous individual before aerosol administration of rAAT; lane 4, lavage fluid from the same Z homozygous individual 24 h after the aerosol administration of 200 mg of rAAT. The relative molecular masses of each type of α1AT are indicated (arrows).
Figure 3. Time course of the augmentation of ELF α1AT levels and ELF anti-neutrophil elastase capacity following aerosol administration of rAAT. rAAT (200 mg) was administered by aerosol to seven α1AT deficient individuals and bronchoalveolar lavage performed at 4 or 24 h later. (A) Total ELF α1AT levels in pre- or postaerosol bronchoalveolar lavage fluid measured by an enzyme linked immunosassay specific for α1AT. (B) Antineutrophil elastase capacity determined by the ability of bronchoalveolar lavage fluid to inhibit a fixed amount of human neutrophil elastase. Concentrations are expressed (log scale) relative to the epithelial lining fluid volume recovered. The range for normal ELF α1AT levels and antineutrophil elastase capacity was determined from analysis of normal subjects (21).

deficient individuals for a significant portion of a 24-h period after aerosol.

Function of recovered rAAT. To further assess the ability of rAAT to function after aerosolization and deposition, rAAT was administered by aerosol to two Nullgranite flls homozygotes, thus permitting assessment of the nature of the interaction between rAAT and neutrophil elastase in the absence of the confounding effects of endogenous α1AT. As expected, ELF of a Nullgranite flls homozygote contained no α1AT (Fig. 4, lane 1). The addition in vitro of rAAT to Nullgranite flls ELF de-

Figure 4. Demonstration that aerosolized rAAT remains intact and functional as an inhibitor of neutrophil elastase (NE) after in vivo administration. Shown is a Western blot analysis of lavage fluid from a homozygous Nullgranite flls individual obtained before and after aerosol administration of rAAT. Lane 1, lavage fluid before rAAT aerosol; lane 2, lavage fluid plus rAAT added in vitro to the lavage fluid; lane 3, lavage fluid plus rAAT and NE added to the lavage fluid in vitro; lane 4, lavage fluid obtained 4 h after aerosol administration of 200 mg rAAT; lane 5, lavage fluid obtained 4 h after aerosol administration of 200 mg rAAT + NE added in vitro. Arrows indicate relative molecular masses.
epithelium and enter the circulation, i.e., the lower respiratory tract epithelium is permeable to rAAT deposited on the alveolar surface by aerosol, suggesting at least some of the rAAT must have reached the alveolar interstitial tissues.

Safety. No adverse reaction was noted among any of the patients receiving rAAT by aerosol. Each aerosol administration was well tolerated and no immediate or late symptoms were noted. No clinical laboratory parameters were significantly changed at 4, 24, or 48 h or 1 mo after aerosol, when compared with the preaerosol values (data not shown). Furthermore, there was no evidence of inflammation developing in the lower respiratory tract as assessed by comparison of the bronchoalveolar lavage fluid cellular constituents of pre- and postaerosol lavage fluid; preaerosol, 21±14×10⁵ total cells recovered, 83±10% macrophages, 12±9% lymphocytes, 4±4% neutrophils; postaerosol, 16±13×10⁵ total cells, 85±16% macrophages, 9±9% lymphocytes, 5±4% neutrophils (P > 0.5 pre- vs. postaerosol, all comparisons). Importantly, aerosol administration of rAAT did not result in development of immunologic sensitization against rAAT. In this regard, skin testing with prick and subcutaneous injection of rAAT, yeast extract, and human α1AT did not demonstrate a positive reaction in any individual before or after aerosol administration of rAAT and no study individual developed serum antibodies to rAAT, yeast extract, or human α1AT.

Discussion

This study demonstrates that aerosol administration of rAAT is a feasible and effective method of augmenting the antielastase defenses of the lower respiratory tract in α1AT deficiency. By using an appropriately designed aerosol-generating system, significant quantities of intact, functional rAAT can be deposited directly on the alveolar epithelial surface, resulting not only in increased α1AT levels and antineutrophil elastase capacity in ELF, but also, due to the permeability of the alveolar epithelium to rAAT, increased levels of rAAT in lung interstitial tissues as well. Administration of rAAT results in dose- and time-dependent changes in ELF α1AT and antineutrophil elastase levels in a manner that suggests that once or twice daily aerosol administration of rAAT should result in sustained levels of antielastase protection to the lower respiratory tract. When interpreted in view of the safety of its administration, as evidenced by the lack of pulmonary, immunologic, or general clinical adverse effect of either single-dose or chronic administration of rAAT, aerosol rAAT administration may constitute a reasonable approach to therapy for α1AT deficiency.

Because the lung has only a limited capacity to produce its own antineutrophil elastase protective screen, the lower respiratory tract is dependent on antielastases produced outside of the lung, principally α1AT (3, 16). The vast majority of α1AT is produced in the liver by hepatocytes and reaches the lung via the circulation; in the normal individual, sufficient α1AT diffuses from plasma into the lung to inhibit the burden of elastase to which the lung is exposed (1, 3, 5, 11). This same concept of augmenting lower respiratory tract antielastase defenses is used in intravenous augmentation therapy for α1AT deficiency, in which plasma purified α1AT is administered intravenously and passively reaches the lung via diffusion from the circulation (2, 5, 6). Using doses of 60 mg/kg per wk, intravenous therapy delivers sufficient α1AT to the lungs to reverse the imbalance between elastase and antielastase at the alveolar surface, where the concentration of α1AT in ELF is ~10% the concentration in plasma (2). In reaching the alveolar epithelial surface, the infused α1AT passes through capillary endothelium, lung interstitium, and finally the alveolar epithelial membrane, in the process providing elastase protection throughout the lung, including the lung interstitium, the critical site requiring protection from elastolytic degradation.

In contrast, aerosol administration uses the opposite approach to augmenting lung antielastase defenses. Once the aerosolized rAAT passes the upper airway anatomic barriers, the first lower respiratory tract tissue reached by aerosolized rAAT is the alveolar epithelium (8). After alveolar deposition, rAAT must traverse through lung tissues in the reverse order traveled by intravenously administered α1AT, moving first through the alveolar epithelium, lung interstitium, and capillary endothelium, ultimately reaching the general circulation. Aerosol administration represents a potentially far more efficient method of delivering rAAT to the alveolar surface than intravenous therapy. In this regard, 4 h after the 200-mg aerosol dose, the ELF α1AT level was ~9 µM. It has been estimated that the total lung ELF volume is ~100 ml, so that a total of 40 mg rAAT, or 20% of the initial dose, is present in ELF. This compares with an efficiency rate of only 2% for the delivery of infused α1AT to the lower respiratory tract (2).

A major question is how effectively aerosol administration provides antielastase protection to the alveolar interstitium, particularly in view of the relatively high degree of resistance to diffusion of macromolecules presented by the alveolar epithelium compared with the endothelial membrane (17, 18). However, several lines of evidence suggest that the aerosolized rAAT is not restricted to the alveolar surface, that it does move from the epithelial surface into lung interstitial tissues. First, as was demonstrated in this study, rAAT gains access to the circulation in α1AT deficient individuals after aerosol administration, thus implying that it passed from the alveolar epithelial surface into lung interstitium and then to the general circulation, either through lung interstitial lymphatic drainage, or...
directly into the circulation through alveolar capillaries. Absorption of some of the aerosolized RAA'T by transport across the oropharynx or the large airways may also occur.

Second, studies in sheep, in which it is possible to directly sample lung interstitial lymph, have shown that after RAA'T aerosol administration, RAA'T is present in lymph draining the lung interstitium, as well as in blood plasma, with an ~10-fold difference in concentration between lung interstitial lymph and plasma, indicating that passage of RAA'T into lung interstitium and lymphatics does occur to a significant degree (8). Although RAA'T and plasma α1AT may have different pharmacokinetics in the lung because of their different structure, these observations are also consistent with studies of aerosolization of plasma α1AT to dogs, showing alveolar deposition and retention for at least 6 h after aerosol (19), and aerosolization to sheep demonstrating passage of plasma α1AT into the pulmonary interstitium (20). Although it is not possible to quantify the amounts of RAA'T reaching lung interstitium after aerosol to humans, nor is it known what levels of α1AT are present in the interstitium of normal individuals, it is nonetheless clear that the aerosol route does result in delivery of some RAA'T throughout the lower respiratory tract.

Aerosol therapy may represent a significant step in reducing the cost of chronic augmentation therapy for α1AT deficiency. Although the costs of the aerosol delivery system and the drug itself cannot be accurately predicted at this time, the major savings for this form of therapy is likely to be in the amount of drug required, because the single greatest cost of augmentation therapy is the cost of the drug itself. Because for a typical 70-kg individual the amount of drug required is reduced from 4,200 mg/wk (for intravenous therapy) to an estimated 1,400 mg/wk (for aerosol therapy), a reduction by two-thirds in the amount of drug needed is possible.

In this context, this investigation is an important first step in demonstrating that aerosolization of RAA'T may constitute effective therapy for α1AT deficiency. With the background knowledge that it is possible to safely administer plasma α1AT to humans twice daily by aerosol (20), and with the safety and biologic efficacy of this study, it is reasonable to justify a study of the chronic administration of RAA'T to humans with α1AT deficiency.

Acknowledgments

We are grateful to Paul Kirk, Ruth Phares, Niek Roosdorp, and Mike Ullman (Cooper Laboratories, Inc., Mountain View, CA) and H.-P. Schnebli (CIBA-GEIGY) for all of their help in developing the recombinant α1-antitrypsin for human use; and Michael Matthay, Cardiovascular Research Institute, Department of Medicine and Physiology, University of California, San Francisco for his helpful advice.

References